Potential Drug Target Or Biomarker: DLK2 (G65989)

Target Name: DLK2

NCBI ID: G65989

DLK2

Potential Drug Target Or Biomarker: DLK2

DLK2 (Protein delta homolog 2) is a gene that encodes a protein known to play a critical role in the development and progression of various diseases, including cancer. The protein is a member of the RNA-protein scaffold family, which is responsible for the formation of RNA structures that can interact with proteins and other biomolecules.

DLK2 is a protein that is expressed in nearly all human tissues and has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is also a potential drug target, with several studies suggesting that inhibiting the activity of DLK2 may be a promising new approach to treating these diseases.

One of the key functions of DLK2 is its role in the formation of RNA-protein scaffolds, which can interact with proteins and other biomolecules. These scaffolds are thought to play a critical role in the regulation of cellular processes, including cell growth, differentiation, and inflammation.

In addition to its role in cell regulation, DLK2 is also implicated in the development and progression of several diseases. For example, studies have suggested that high levels of DLK2 expression are associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential role in the development of neurodegenerative diseases, DLK2 has also been implicated in the development and progression of autoimmune disorders. These disorders are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage.

As a potential drug target, DLK2 has been the subject of several studies in recent years. These studies have suggested that inhibiting the activity of DLK2 may be a promising new approach to treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key advantages of targeting DLK2 is its effects are reversible. This is because the activity of DLK2 is dependent on its expression level, which can be easily manipulated by drugs. Additionally, DLK2 is thought to be involved in a wide range of cellular processes, which makes it a potentially attractive target for drugs that can affect multiple cellular processes.

In addition to its potential as a drug target, DLK2 is also a potential biomarker. This is because its expression levels can be easily measured and its effects on cellular processes can be measured. This makes it a potentially useful tool for the diagnosis and treatment of diseases.

Overall, DLK2 is a protein that has the potential to be a drug target or biomarker. Its role in the formation of RNA-protein scaffolds and its involvement in the development and progression of various diseases make it a promising target for drugs that can affect cellular processes. Additionally, its reversible effects and potential as a biomarker make it a promising tool for the diagnosis and treatment of diseases.

Protein Name: Delta Like Non-canonical Notch Ligand 2

Functions: Regulates adipogenesis

The "DLK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets